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suggest that the cost burden of advanced melanoma to the Medi-
care system is high. Efforts to address the large unmet treatment
need in patients with advanced melanoma may result in cost
savings for Medicare.
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OBJECTIVE: To estimate direct medical costs of breast cancer
(BC) by stage of clinical disease in the Ginecology Hospital of
West Medical Center, Instituto Mexicano del Seguro Social
(IMSS), Guadalajara (GH). METHODS: Clinical data and
resource utilization were obtained individually from medical
records of patients who were breast cancer diagnosed and
received attention at GH between March 2005 and February
2007. This data was retrospectively collected with the following
inclusion criteria: 1) histopathologic-study conﬁrmed BC, 2)
recently diagnosed BC, and 3) absence of any other form of
cancer. Only direct medical costs were considered (from the
GH perspective) using a bottom up approach (medications,
chemotherapy, radiotherapy, hospitalization, laboratory tests
and surgery). Unitary costs were obtained from GH’s Manage-
ment. cost are expressed in USD and adjusted to December 2006.
A discount rate of 3% was used. Tests were applied in order to
deﬁne the censoring mechanism (according to Glick) to deﬁne the
adequate cost analysis method. To compare costs among stage
was use ANOVA. Mean Cost estimation (TMC) determinants
were obtained using a generalized linear Model (GLM).
RESULTS: A total of 160 patients were included, 40 in each stage
(I, II, III, IV), mean age 50 years (11), with a therapy duration
of 29 months (11). 82% of patients showed ductal-inﬁltranting
histologic type carcinoma. TMC per patient during the follow-up
period was ($20,612.00). Chemotherapy was the most costly
resource ($7526.10) followed by the visit to the specialist
and emergency room ($3581.88) and hospitalization costs
($3096.45). GLMxs statistically-signiﬁcant TMC determinants
were stage II, III and IV (p < 0.00), disease progression (p < 0.00)
death (p < 0.00) and age (p < 0.046). CONCLUSION: The direct
cost in medical attention increases with stage, progression of
disease or patient death, stage IV, less age, longer duration of
treatment and disease progression, effectively predicted major
costs.
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OBJECTIVE: To develop an economic analysis of the manage-
ment of pleural effusions in CML patients receiving dasatinib.
METHODS: A cost of treatment analysis was developed using
resource utilization data published for 48 patients with
dasatinib-related pleural effusions at a large cancer center. Costs
were derived from median reimbursements for relevant CPT
codes for outpatient services and medical literature for inpatient
services. The base case analysis assumed 100% incurred two
additional physician visits, two chest x-rays, and a course of
diuretics; 37.5% ECHO; 30% steroids; 24% recurrent effusions;
19% multiple thoracentesis procedures; 4% chest tube; 4%
Denver shunt; and 2% pericardial window. Sensitivity analyses
were conducted for types of procedures used. All costs were
adjusted to 2007 US dollars. RESULTS: Of pleural effusions
reported, 58% involved  25% of one lung volume and were
managed medically costing $750 per episode, including physician
visits, ECHO, chest X-rays and medications. The other 42% of
pleural effusions were more signiﬁcant, involving 26%–>75% of
one lung volume, with half of those patients requiring invasive
procedures. The cost of invasive procedures for inpatient man-
agement of pleural effusions was $10,616 for chest tube, $15,170
with pleural catheter, and $15,344 for pericardial window. The
cost of invasive outpatient management ranged from $713 for
ultrasound thoracentesis to $4598 for pleural catheter. The
average cost of treating a pleural effusion adverse event (includ-
ing all severity levels) ranged from $2062 to >$3000 depending
on whether thoracentesis or placement of pleural catheter was
utilized. Important drivers included recurrent effusions. CON-
CLUSION: This economic analysis based on actually observed
treatment patterns suggests that the management of pleural effu-
sions in CML patients receiving dasatinib is costly and requires
intensive resource utilization. Effective tyrosine kinase inhibitors
with lower rates of pleural effusions may represent clinically
and economically valuable alternatives for imatinib-resistant or
-intolerant CML patients.
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OBJECTIVE: The 2006 American Society of Clinical Oncology
guideline recommends primary prophylaxis (PP) with colony-
stimulating factor (CSF) for elderly patients with diffuse aggres-
sive lymphoma receiving chemotherapy, based on the assumption
of equal survival and studies showing that CSF saved costs by
reducing hospitalization from febrile neutropenia (FN). These
analyses examined only one cycle of chemotherapy, and did not
consider the costs of CSF in subsequent cycles, the strategy of
secondary prophylaxis (SP) or patients’ preferences. This study
examined the cost-effectiveness of PP with SP. METHODS: We
conducted a cost-utility analysis to compare PP with CSF to SP
with CSF for diffuse aggressive lymphoma. We used a Markov
cohort model with a time horizon of 8 cycles of chemotherapy
(i.e. 24 weeks), using a payer’s perspective (Ontario Ministry of
Health). Ontario’s 2006 health economic data was used. The
cost of hospitalization for FN was obtained from Ontario Case
Costing Initiative. Data for efﬁcacies of CSF, probabilities and
utilities were obtained from published literature. Monte Carlo
simulation was conducted. RESULTS: The ICER of PP to SP was
$739,999/QALY. One-way sensitivity analyses (willingness-to-
pay threshold =$100,000) showed that if PP were to be cost-
effective, the cost of hospitalization for FN had to be >$31,138
(2.5 times > base case), the cost of CSF per cycle <$96 (base case
= $1960), the risk of 1st cycle FN >48% (base case = 24%), or
the relative risk reduction of FN with CSF >97% (base case =
41%). Our result was robust to all variables. Second order
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